## Bone marrow amyloidosis

## Haematologica 2006; 91:(1)e16

A 54-year-old man presented with nephrotic syndrome, renal impairment and restrictive cardiomyopathy. On admission, physical examination revealed pallor, peripheral edema and moderate hepatosplenomegaly. Hematologic values were: Hb 9.7 g/dL, WBC 10.4×10<sup>9</sup>/L with a normal differential count, platelets  $109 \times 10^{\circ}/L$ . Kappa monoclonal light chains were identified by urine immunofixation. Circulating kappa free light chains were 378 mg/L and lambda 56.3 mg/L. Bone marrow aspirate displayed slightly hypocellular marrow with maturing hematopoietic progenitors and mild dyserythropoiesis. There were 8% morphologically normal plasma cells. Various-sized clumps of pink amorphous material were scattered on the smears (Figure, A and B). These deposits stained with Congo red (Figure, C), that under polarized light produced a characteristic applegreen birefringence (Figure, D). Abdominal fat pad aspirate confirmed the presence of amyloid. Therefore, a diagnosis of AL amyloidosis with renal, cardiac and bone marrow involvement was made. The patient was treated with high-dose dexamethasone with progressive improvement of his condition.

Systemic AL amyloidosis is a plasma cell dyscrasia in which the fibril amyloid protein is produced by monoclonal plasma cells and consists of whole or fragments of immunoglobulin light chains.<sup>1</sup> It is associated with plasma cell myeloma in about 15% of cases. In the other cases a moderate monoclonal increase in plasma cells is usually present in the bone marrow.<sup>2</sup> A monoclonal immunoglobulin is found in the serum or urine in more than 80% of patients. Amyloid deposits are detected in blood vessels and as interstitial foci in bone marrow sections in approximately 60% of patients,<sup>2,3</sup> but very rarely, and only when there is extensive bone marrow involvement, extracellular amyloid clumps are present in a bone marrow aspirate.

Rosangela Invernizzi,<sup>4</sup> Giovanni Palladini,<sup>42</sup> Chiara Benatti,<sup>4</sup> Erica Travaglino,<sup>4</sup> Mario Nuvolone,<sup>2</sup> Giampaolo Merlini<sup>2</sup> <sup>4</sup>Department of Internal Medicine, <sup>2</sup>Center for Amyloidosis, Biotechnology Research Laboratories, University of Pavia and IRCCS Policlinico S. Matteo, Pavia, Italy

Correspondence: R. Invernizzi, M.D., Clinica Medica III, Policlinico S. Matteo, Piazzale Golgi, 27100 Pavia (Italy) E-mail: r.invernizzi@smatteo.pv.it

## References

- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-96.
- Kyle ŘA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.
- Swan N, Skimmer M, O'Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. Am J Clin Pathol 2003; 120:610-6.